ライフサイエンスコーパス: nasopharyngeal

1 We developed a 3D-printed nasopharyngeal (3DP) swab as a replacement of the FLNP s

2 dy was to investigate whether a preinstalled nasopharyngeal airway (NPA) in the right nasal passagewa

3 atistically significant interactions between nasopharyngeal airway CCL5 levels and microbiota profile

4 Nasopharyngeal airway metabolome profiles significantly

5 To determine the relations among the nasopharyngeal airway metabolome profiles, microbiome pr

6 We also profiled the nasopharyngeal airway microbiota and examined its associ

7 genome shotgun sequencing) approaches to 144 nasopharyngeal airway samples collected within 24 hours

8 dings of novel coronavirus testing on pooled nasopharyngeal and bronchoalveolar lavage samples taken

9 9]; p<0.05 for all 58 taxa) was high between nasopharyngeal and endotracheal aspirate samples, suppor

10 Nasopharyngeal and oropharyngeal (adults only) swabs und

11 Nasopharyngeal and oropharyngeal (NP/OP) specimens were

12 Nasopharyngeal and oropharyngeal paired samples (599 eac

13 Nasopharyngeal and oropharyngeal swabs were collected du

14 ssenting residents of the facility underwent nasopharyngeal and oropharyngeal testing for SARS-CoV-2,

15 s coronavirus disease 2019 (COVID-19)-in 154 nasopharyngeal and throat swab samples collected at Siri

16 omparable to that of the current standard of nasopharyngeal and throat swabs.

17 94% of rectal, 79% of oropharyngeal, 56% of nasopharyngeal, and 20% of cerebrospinal fluid specimens

18 Juvenile nasopharyngeal angiofibroma (JNA) showed distinctly high

19 mycobacterial culture and Xpert MTB/RIF, and nasopharyngeal aspirate multiplex PCR.Measurements and M

20 Nasopharyngeal aspirate samples were analyzed with polym

21 Tonsillar tissue, nasopharyngeal aspirate, and serum were obtained from 18

22 n whom real-time PCR for RV was performed in nasopharyngeal aspirates (NPAs) and bronchoalveolar lava

23 ts and Main Results: Induced sputum (IS) and nasopharyngeal aspirates (NPAs) were obtained.

24 ing was performed for respiratory viruses in nasopharyngeal aspirates collected from children aged <5

25 real-time polymerase chain reaction to test nasopharyngeal aspirates for 16 viruses.

26 Nasopharyngeal aspirates were analyzed with semiquantita

27 Nasopharyngeal aspirates were tested for influenza and R

28 new rapid test, on repeated induced sputum, nasopharyngeal aspirates, and combinations of specimens.

29 Infants were sampled by nasosorption and nasopharyngeal aspiration (NPA).

30 serotypes may mitigate the impact of PCV7 on nasopharyngeal bacterial community structure and ecology

31 The nasopharyngeal bacterial load was assessed in naive anim

32 ic infection is associated with an increased nasopharyngeal bacterial load, with subsequent developme

33 capacity for NTHi phagocytosis and increased nasopharyngeal bacterial loads in ccl3(-/-) mice.

34 In infants, distinct nasopharyngeal bacterial microbiotas differentially asso

35 At baseline, participants will have nasopharyngeal, blood, buccal, stool, and urine samples

36 e associated with pathways known to regulate nasopharyngeal, breast, melanoma, and bladder carcinogen

37 our method by validating its predictions in nasopharyngeal cancer and colorectal cancer using whole

38 o cancers with an epithelial origin, such as nasopharyngeal cancer and gastric cancer, as well as mul

39 nd migration of EBV-related cancers, such as nasopharyngeal cancer and gastric cancer.

40 rally infected epithelial gastric cancer and nasopharyngeal cancer cell lines.

41 oliferation, migration, invasion, and EMT in nasopharyngeal cancer cells.

42 can cause various human malignancies such as nasopharyngeal carcinoma (NPC) and gastric cancer (GC).

43 ions to tumorigenesis and chemoresistance in nasopharyngeal carcinoma (NPC) are not evident.

44 the correlation between APLNR expression and nasopharyngeal carcinoma (NPC) has not been reported.

45 Serological testing for nasopharyngeal carcinoma (NPC) has recently been reinvig

46 Nasopharyngeal carcinoma (NPC) is a highly metastatic ca

47 Nasopharyngeal carcinoma (NPC) is an aggressive head and

48 Nasopharyngeal carcinoma (NPC) is an invasive cancer wit

49 reatment of EBV-associated cancer.IMPORTANCE Nasopharyngeal carcinoma (NPC) is highly associated with

50 ostic tools for monitoring disease status in nasopharyngeal carcinoma (NPC) patients.

51 enhancing in vivo detection and diagnosis of nasopharyngeal carcinoma (NPC) patients.

52 Given salvage treatment for recurrent nasopharyngeal carcinoma (NPC) remains a clinical dilemm

53 de polymorphisms (SNPs) in PIN1 promoter and nasopharyngeal carcinoma (NPC) risk with a small sample

54 frequently present in Chinese and Indonesian nasopharyngeal carcinoma (NPC) samples.

55 Genetic susceptibility is likely involved in nasopharyngeal carcinoma (NPC), a cancer caused by Epste

56 's lymphoma, diffuse large B-cell lymphomas, nasopharyngeal carcinoma (NPC), and lymphomas that devel

57 g tumors that have latent infection, such as nasopharyngeal carcinoma (NPC), and oral hairy leukoplak

58 survival rates in cancer patients, including nasopharyngeal carcinoma (NPC), breast cancer and hepato

59 associated with many human cancers, such as nasopharyngeal carcinoma (NPC), Hodgkin's disease, and g

60 s (EBV) have been proposed for screening for nasopharyngeal carcinoma (NPC).

61 associated with multiple cancers, including nasopharyngeal carcinoma (NPC).

62 nvolved in ATRA-induced growth inhibition of nasopharyngeal carcinoma and may suppress EMT through PI

63 llular accumulation of HIF-1alpha of hypoxic nasopharyngeal carcinoma cells and mediates the radiatio

64 s type I interferon production, and in human nasopharyngeal carcinoma cells results in almost complet

65 s the radiation-resistant phenotype of these nasopharyngeal carcinoma cells.

66 We further demonstrate in nasopharyngeal carcinoma CNE2 and 5-8F cells that this c

67 ts in the hypoxic regions of tumor formed by nasopharyngeal carcinoma CNE2 cells and breast cancer MD

68 The treatment of childhood nasopharyngeal carcinoma has been adapted from adult reg

69 Nasopharyngeal carcinoma is characterised by distinct ge

70 ry leukoplakia) or latent infection (such as nasopharyngeal carcinoma).

71 olleagues report these results for recurrent nasopharyngeal carcinoma, an aggressive malignancy assoc

72 Notable exceptions were observed for nasopharyngeal carcinoma, an EBV-associated cancer, and

73 a herpesvirus linked to malignancies such as nasopharyngeal carcinoma, Burkitt's lymphoma, and Hodgki

74 at are consistently EBV genome positive (eg, nasopharyngeal carcinoma, endemic Burkitt lymphoma), thi

75 d with several human malignancies, including nasopharyngeal carcinoma, gastric cancer, and lymphoma.

76 hogen associated with Burkitt's lymphoma and nasopharyngeal carcinoma.

77 nd represent a promising future direction in nasopharyngeal carcinoma.

78 epistaxis for 2 years and was diagnosed with nasopharyngeal carcinoma.

79 rr virus (EBV) causes Burkitt's lymphoma and nasopharyngeal carcinoma.

80 cies Hodgkin and Burkitt lymphoma as well as nasopharyngeal carcinoma.

81 actionated radiotherapy, or including mostly nasopharyngeal carcinomas were excluded.

82 man herpesvirus, is latently present in most nasopharyngeal carcinomas, Burkitt lymphomas, and some g

83 We aimed to assess PCV10 effect against nasopharyngeal carriage and invasive pneumococcal diseas

84 PCV impact on ANSP nasopharyngeal carriage is a dynamic, multicomponent pro

85 ram-negative bacterium with an oropharyngeal/nasopharyngeal carriage niche that is associated with a

86 jective was to demonstrate that asymptomatic nasopharyngeal carriage of Bordetella pertussis is induc

87 Nasopharyngeal carriage of PCV7 serotypes in Group 1 was

88 haled exposure to DEPs disrupts asymptomatic nasopharyngeal carriage of S pneumoniae in mice, leading

89 ould promote the progression of asymptomatic nasopharyngeal carriage of Streptococcus pneumoniae to i

90 Nasopharyngeal carriage prevalence of pneumococcus was m

91 sess PCV carriage using rolling, prospective nasopharyngeal carriage surveys between 2015 and 2018, 3

92 ease course evolves from one of asymptomatic nasopharyngeal carriage to overt disease.

93 Annual cross-sectional surveys of nasopharyngeal carriage were done from 2009 to 2016.

94 e patterns, altering density of pneumococcal nasopharyngeal carriage, reducing phagocytic killing, an

95 arried at higher densities than ST618 during nasopharyngeal carriage.

96 ngitidis can be transmitted via asymptomatic nasopharyngeal carriage.

97 persons, with higher rates among those with nasopharyngeal carriage.

98 n-adapted pathogen, is driven principally by nasopharyngeal carriage.

99 act of smoking on microbial residents of the nasopharyngeal cavity, in contact with cigarette smoke (

100 lymphomas as well as epithelial cell-derived nasopharyngeal cell carcinoma.

101 killing, biofilm production, and adhesion to nasopharyngeal cells, though serotype 33F survived short

102 biofilm formation, and increased adhesion to nasopharyngeal cells.

103 Nasopharyngeal collections were obtained every 3-4 days

104 In a mouse nasopharyngeal colonisation model, black carbon caused S

105 is atypical in that it is rarely found as a nasopharyngeal coloniser, yet is described as one of the

106 ile baboons with BPZE1 resulted in transient nasopharyngeal colonization and induction of immunoglobu

107 m the failure of current vaccines to prevent nasopharyngeal colonization by Bordetella pertussis, the

108 C and Spd1 act synergistically to facilitate nasopharyngeal colonization in a mouse model.

109 his cohort of pre-school asthmatic children, nasopharyngeal colonization with Gram-negative bacteria

110 Nasopharyngeal colonization with nontypeable Haemophilus

111 Streptococcus pneumoniae is a common nasopharyngeal colonizer, but can also cause life-threat

112 Neisseria meningitidis (Nm) is a nasopharyngeal commensal carried by healthy individuals.

113 us pneumoniae (the pneumococcus) is a common nasopharyngeal commensal that can cause invasive pneumoc

114 Nasopharyngeal cultures for S. pneumoniae were obtained

115 Nasopharyngeal cultures were processed for pneumococcal

116 Pathogens are presumed to originate from the nasopharyngeal ecosystem.Objectives: To investigate the

117 NPC patients and 48 healthy subjects during nasopharyngeal endoscopic examinations.

118 f NPC at the molecular level during clinical nasopharyngeal endoscopy.

119 nate immune defense protein expressed in the nasopharyngeal epithelia; however, its role in invasive

120 pression in both pre-malignant and malignant nasopharyngeal epithelial (NPE) cells.

121 se to infection - under bacterial stimuli in nasopharyngeal epithelial cells.

122 ed in NPC tissues compared with noncancerous nasopharyngeal epithelial tissues.

123 lies required for testing, including flocked nasopharyngeal (FLNP) swabs.

124 HMPV - S. pneumoniae can become part of the nasopharyngeal flora, contributing to the severity of re

125 body-mediated depletion of T cells prevented nasopharyngeal infection by S. pyogenes, but not by Stre

126 nipulate Vbeta-specific T cells to establish nasopharyngeal infection.

127 onfunctional SpeA mutant, protects mice from nasopharyngeal infection; however, only passive immuniza

128 hial lymph node, retropharyngeal lymph node, nasopharyngeal lymph node and pharyngeal tonsil collecte

129 evidence suggests relationships between the nasopharyngeal metabolome and both the microbiota and se

130 clinical, RV species (RV-A, RV-B, and RV-C), nasopharyngeal microbiome (16S rRNA gene sequencing), cy

131 carriage and the bacterial component of the nasopharyngeal microbiome during infancy.

132 ed whether developmental trajectories of the nasopharyngeal microbiome in early life and the composit

133 mic signatures were associated with both the nasopharyngeal microbiota and the severity of bronchioli

134 erium, and Janthinobacterium lividum, in the nasopharyngeal microbiota before and during RTIs, which

135 Our data suggest that the nasopharyngeal microbiota can serve as a valid proxy for

136 Nasopharyngeal microbiota composition is associated with

137 ur previously published associations between nasopharyngeal microbiota development and susceptibility

138 cohort of 112 infants, we characterized the nasopharyngeal microbiota longitudinally from birth on (

139 Blood biomarkers and nasopharyngeal microbiota profiles were determined by us

140 tract microbiota during LRTIs and the use of nasopharyngeal microbiota to discriminate LRTIs from hea

141 The relation of nasopharyngeal microbiota to the clearance of respirator

142 ular samples/subject) and compared them with nasopharyngeal microbiota using 16S-rRNA-based sequencin

143 iation with allergy/inflammatory biomarkers, nasopharyngeal microbiota, and development of recurrent

144 itis, rhinovirus species related to distinct nasopharyngeal microbiota.

145 re acute respiratory syndrome-coronavirus 2, nasopharyngeal, mid turbinate, and nasal specimens are s

146 nt finding of asymptomatic ocular, oral, and nasopharyngeal MMP is clinically significant and implies

147 relative abundance of CD8(+) T cells in the nasopharyngeal mucosa in association with clearance of F

148 demonstrated that clearance of FMDV from the nasopharyngeal mucosa was associated with upregulation o

149 d Origins of Asthma study (N = 285) provided nasopharyngeal mucus samples in the first 2 years of lif

150 d contributes to mucosal host defense of the nasopharyngeal niche, a reservoir for ME and upper respi

151 We collected and tested nasopharyngeal (NP) specimens by RT-PCR two or more time

152 In this study, nasopharyngeal (NP) specimens collected from patients in

153 In this report, we analyzed 749 nasopharyngeal (NP) specimens collected in 2015 and 2016

154 Sequencing of IAV genomes from available nasopharyngeal (NP) specimens identified 66 individuals

155 that includes an RNA extraction step from a nasopharyngeal (NP) swab followed by reverse transcripti

156 nvestigated host gene expression profiles in nasopharyngeal (NP) swabs and whole blood samples during

157 sex among shotgun RNA sequencing profiles of nasopharyngeal (NP) swabs from 430 individuals with PCR-

158 Inclusion criteria were (a) positive nasopharyngeal or lower respiratory tract reverse transc

159 We performed nasopharyngeal or nasal swabbing and/or serum sampling (

160 We collected nasopharyngeal or nasal swabs at enrollment and tested f

161 New diagnostic platforms often use nasopharyngeal or oropharyngeal (NP/OP) swabs for pathog

162 the first study, nasal specimens and either nasopharyngeal or oropharyngeal specimens from 251 parti

163 g tissue infection by, SARS-CoV-2 in sputum, nasopharyngeal or oropharyngeal, urine, stool, blood and

164 The device correctly classified all nasopharyngeal, oropharyngeal and sputum samples from 75

165 rganism detection by multiplex PCR in IS and nasopharyngeal/oropharyngeal (NP/OP) specimens.

166 Nasopharyngeal/oropharyngeal (NP/OP) swabs from 70 child

167 However, nasopharyngeal/oropharyngeal (NP/OP) swabs may not accur

168 -59 months investigating pathogens in blood, nasopharyngeal/oropharyngeal (NP/OP) swabs, and induced

169 cases, and with high (>6.9 log10 copies/mL) nasopharyngeal/oropharyngeal load and C-reactive protein

170 reaction [PCR]) compared to "RSV pneumonia" (nasopharyngeal/oropharyngeal or induced sputum PCR-posit

171 d PCR-confirmed COVID-19, and 29 either were nasopharyngeal/oropharyngeal PCR negative or presented f

172 The two stool PCR-positive, nasopharyngeal/oropharyngeal PCR-negative patients were

173 Nasopharyngeal/oropharyngeal specimens were tested for H

174 tative polymerase chain reaction analysis of nasopharyngeal/oropharyngeal specimens.

175 Nasopharyngeal/oropharyngeal swabs (NOPS) from 7663 pati

176 monia from January 2010-June 2012 and tested nasopharyngeal/oropharyngeal swabs for Mp using real-tim

177 Nasopharyngeal/oropharyngeal swabs from children (1 to 5

178 In the 9 developing country sites, nasopharyngeal/oropharyngeal swabs from children with an

179 In 7 low- and middle-income countries, nasopharyngeal/oropharyngeal swabs from children with se

180 Specimen types tested included nasopharyngeal/oropharyngeal swabs in the above-named tr

181 Venous blood and nasopharyngeal/oropharyngeal swabs were collected from a

182 We validate SHINE on 50 nasopharyngeal patient samples, demonstrating 90% sensit

183 2014 and August 2015 ("late PCV13"), and had nasopharyngeal pneumococcal carriage compared with 7-val

184 psonophagocytic capacity was correlated with nasopharyngeal pneumococcal density (r = 0.61, P = 0.025

185 Nasopharyngeal pneumococcal density was higher in pediat

186 We analyzed data on vaccination and nasopharyngeal pneumococcal detection among children <5

187 Nasopharyngeal pneumococci were molecular-serotyped by m

188 han NOP children, due to deficient antiviral nasopharyngeal proinflammatory cytokine and chemokine re

189 uring viral URIs, and examined the different nasopharyngeal responses between viral URI events and th

190 .047) and GM-CSF (P = 0.050) were higher and nasopharyngeal RT-PCR cycle threshold values lower (P =

191 lt on polymerase chain reaction testing of a nasopharyngeal sample among patients requiring admission

192 rmed by the central laboratory on a baseline nasopharyngeal sample, and had received at least one dos

193 rences were observed between both methods in nasopharyngeal samples (5.4% vs. 5.4% in the nursing hom

194 heal aspirate samples, supporting the use of nasopharyngeal samples as proxy for lung microbiota duri

195 the interpretation of the presence of HRV in nasopharyngeal samples for attribution of a causal role

196 Nasopharyngeal samples for viral load quantitation, typi

197 Main Results: HMGB1 levels were elevated in nasopharyngeal samples of children with acute RSV infect

198 Deep sequencing of nasopharyngeal samples produced partial sequences for 4

199 Collection of nasopharyngeal samples using swabs followed by the trans

200 (high mobility group box 1) release.Methods: Nasopharyngeal samples were collected from children pres

201 Nasopharyngeal samples were obtained at admission for ca

202 ata with Aries Bordetella Assay data from 57 nasopharyngeal samples with previously confirmed B. pert

203 Of 8446 nasopharyngeal samples, 48.3% were positive (42.0% and 5

204 XCL10/IP-10 and GM-CSF, together with higher nasopharyngeal SARS-CoV-2 viral load, were associated wi

205 gainst SARS-CoV-2 under conditions mimicking nasopharyngeal secretions.

206 Cal09 showed impaired pH1N1 nasopharyngeal shedding (16 of 118 children [14%, 95% CI

207 OPS is an acceptable alternative specimen to nasopharyngeal specimen for the detection of SARS-CoV-2.

208 e study period, including 2130 POPS and 8438 nasopharyngeal specimens (NPsp).

209 Results for NAATs performed on nasopharyngeal specimens and repeated within 90 days aft

210 Repeat testing of nasopharyngeal specimens before 20 days demonstrates lit

211 16 S rRNA gene sequencing were performed on nasopharyngeal specimens collected at regular intervals

212 y was then used to test IAV rRT-PCR positive nasopharyngeal specimens collected from individuals expo

213 es, 11 767 otitis media (OM) cases, and 1587 nasopharyngeal specimens collected from Israeli children

214 swabs, had about the same sensitivity as did nasopharyngeal specimens for influenza virus detection b

215 During the study period, 21,819 nasopharyngeal specimens from 16,779 individuals were su

216 Of 1,052 nasopharyngeal specimens from patients with suspected pe

217 Between 2010 and 2012, nasopharyngeal specimens were collected from healthy ind

218 acheal aspirate; all previous and concurrent nasopharyngeal specimens were negative.

219 training and technique in the collection of nasopharyngeal specimens.

220 ated RT-PCR assays, with a collection of 389 nasopharyngeal specimens.

221 on polymerase chain reaction was negative in nasopharyngeal, stool, and respiratory samples and was p

222 verse-transcription (RT) PCR were applied to nasopharyngeal swab (NPS) samples from all acutely HBoV1

223 nd Bordetella parapertussis nucleic acids in nasopharyngeal swab (NPS) samples.

224 tive detection of 20 pathogens directly from nasopharyngeal swab (NPS) specimens.

225 cute respiratory syndrome coronavirus 2 from nasopharyngeal swab and cerebral spinal fluid.

226 participants with virus detectable by PCR in nasopharyngeal swab at day 3, and was assessed in partic

227 s detectable by polymerase chain reaction in nasopharyngeal swab at day 3.

228 -2 infection by polymerase chain reaction of nasopharyngeal swab or serology.

229 COVID-19 was diagnosed by a positive nasopharyngeal swab RT-PCR for SARS-CoV-2 infection.

230 est was assessed by comparing results of 100 nasopharyngeal swab samples previously characterized by

231 Nasopharyngeal swab samples were collected and cultured

232 etection in microwells, both from buffer and nasopharyngeal swab samples, and presented superior sing

233 n-polymerase chain reaction assay applied to nasopharyngeal swab samples.

234 utomated purification of target RNA from raw nasopharyngeal swab samples.

235 about 35 min for both contrived and clinical nasopharyngeal swab samples.

236 elded negative results by IDNOW had a paired nasopharyngeal swab specimen collected in VTM and tested

237 Clinical nasopharyngeal swab specimen testing (n = 140) showed 10

238 systematic random sampling to identify 3,000 nasopharyngeal swab specimens collected from January 200

239 The LFIA reacted with patient nasopharyngeal swab specimens containing as few as 1.8 x

240 sal) swab specimens, and clinician-collected nasopharyngeal swab specimens for the detection of SARS-

241 polymerase chain reaction assays applied to nasopharyngeal swab specimens in 100 patients with cance

242 old from January to April 2018 and collected nasopharyngeal swab specimens in viral medium.

243 A total of 200 nasopharyngeal swab specimens in viral transport medium

244 Of the 2,479 eligible nasopharyngeal swab specimens included in the prospectiv

245 onavirus species, including SARS-CoV; and 85 nasopharyngeal swab specimens positive for other respira

246 linical samples comparing the data using the nasopharyngeal swab specimens tested with Real-Time PCR.

247 pertussis and B. parapertussis directly from nasopharyngeal swab specimens.

248 tiating B. pertussis and B. parapertussis in nasopharyngeal swab specimens.

249 s performed similarly to clinician-collected nasopharyngeal swab specimens.

250 ing with influenzalike illness who underwent nasopharyngeal swab testing for influenza and respirator

251 media (e.g., blood, saliva and oropharyngeal/nasopharyngeal swab) through interaction with active fun

252 ID-19) pandemic has resulted in shortages of nasopharyngeal swabs (NPS) and viral transport media, ne

253 tively compared health care worker-collected nasopharyngeal swabs (NPS) to self-collected anterior na

254 A was evaluated using retrospective, remnant nasopharyngeal swabs (NPS), previously tested by FilmArr

255 sting (NAAT) of viral samples retrieved with nasopharyngeal swabs (NPSs).

256 We obtained paired nasopharyngeal swabs and deep endotracheal aspirates fro

257 rove HUDSON to rapidly inactivate viruses in nasopharyngeal swabs and saliva in 10 min.

258 We analyzed nasopharyngeal swabs and vaccination histories from 5928

259 We analyzed nasopharyngeal swabs and vaccination histories from 5928

260 d, including PCR cycle threshold values from nasopharyngeal swabs and viral shedding in blood, urine,

261 Nasopharyngeal swabs collected from household contacts e

262 Transcriptional profiling of nasopharyngeal swabs demonstrated that in addition to ty

263 and the presence of SARS-CoV-2 infection in nasopharyngeal swabs for 85.9% and 71.5% of the populati

264 workflow for the detection of SARS-CoV-2 in nasopharyngeal swabs from 108 symptomatic patients.

265 Lung aspirates and nasopharyngeal swabs from 31 patients were examined by c

266 We systematically collected nasopharyngeal swabs from asymptomatic patients during s

267 emergency use authorization by the FDA using nasopharyngeal swabs from symptomatic patients: the New

268 positive by Cepheid Xpert Xpress when using nasopharyngeal swabs in viral transport media and 45% wh

269 rs, whole genome sequencing was performed on nasopharyngeal swabs of all individuals including the re

270 aused a severe international shortage of the nasopharyngeal swabs that are required for collection of

271 19 and Cepheid Xpert Xpress SARS-CoV-2 using nasopharyngeal swabs transported in viral transport medi

272 19 and Cepheid Xpert Xpress SARS-CoV-2 using nasopharyngeal swabs transported in viral transport medi

273 omes were the reduction of viral RNA load in nasopharyngeal swabs up to 7 days after treatment start,

274 se 2019 (COVID-19) had persistently positive nasopharyngeal swabs up to day 16 of admission.

275 Nasopharyngeal swabs were analyzed by multiplex polymera

276 Nasopharyngeal swabs were analyzed by phenotypic and gen

277 Nasopharyngeal swabs were collected >- 30 days after ser

278 Nasopharyngeal swabs were collected according to WHO rec

279 ARS-CoV-2 RNA from clinical specimens (e.g., nasopharyngeal swabs).

280 set of 447 single-end total RNA samples from nasopharyngeal swabs, and establish the applicability of

281 phenotyping, quantitative real-time PCR from nasopharyngeal swabs, and SARS-CoV-2 antibody status wer

282 atus was confirmed by PCR testing of sputum, nasopharyngeal swabs, or throat swabs.

283 on but not of neutralizing antibodies in her nasopharyngeal swabs.

284 Panther, and Roche Cobas) on a total of 169 nasopharyngeal swabs.

285 Respiratory viruses were identified from nasopharyngeal swabs.

286 +/- 41.2 min for DHCA; p < 0.05) and higher nasopharyngeal temperature (26.0 +/- 2.1 vs 18.9 +/- 1.6

287 COVID-19 five or more days after a positive nasopharyngeal test by PCR with reverse transcription.

288 y tested positive on rectal swabs even after nasopharyngeal testing was negative, raising the possibi

289 history, and saliva at enrollment and daily nasopharyngeal/throat swabs (NTSs) for RT-PCR testing.

290 lity in symptoms, we found no differences in nasopharyngeal viral load by age or between symptomatic

291 Serial nasopharyngeal viral loads were determined using a quant

292 ial antiviral effects of azithromycin on the nasopharyngeal virome of Nigerien children who had recei

293 Total postchallenge nasopharyngeal virulent bacterial burden of vaccinated a

294 Nasopharyngeal VLs by polymerase chain reaction and CDSS

295 Nasopharyngeal wash (NPW) specimens were collected on da

296 Nasopharyngeal wash specimens from case patients and con

297 d specimen collection criteria, we collected nasopharyngeal washes for testing by singleplex reverse-

298 sis cells in buffer, 6.2 x 10(5) CFU/mL with nasopharyngeal washes from a non-human primate model, an

299 Respiratory virus presence in nasopharyngeal washes was studied at illness visits and

300 In 312 nasopharyngeal washings positive for RSV, we sequenced t